Ruxolitinib (a JAK2 inhibitor) and belumosudil (a ROCK2 inhibitor) have recently been approved by the Food and Drug Administration (FDA) for the treatment of chronic graft-versus-host disease (GVHD).

More than half of patients had an objective response to first-line nivolumab for locally advanced or metastatic cutaneous squamous cell carcinoma, phase 2 study results published in Cancer showed.